Related Experiment Video
Updated: Apr 15, 2026
08:33
Author Spotlight: Methodologies and Advancements of Chronic Pain Management Research
Published on: January 5, 2024
2.0K
Dalfampridine in hereditary spastic paraplegia: a prospective, open study
Matthieu Béreau1, Mathieu Anheim, Jean-Baptiste Chanson
1Département de Neurologie, CHRU de Besançon, Besançon, France.
Journal of Neurology
|March 27, 2015
Summary
Dalfampridine shows promise for treating hereditary spastic paraplegia (HSP). This study found significant improvements in walking ability and quality of life for HSP patients using this treatment.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Hereditary spastic paraplegia (HSP) is a group of inherited neurological disorders.
- Current treatments for HSP symptoms, particularly gait impairment, are limited.
Purpose of the Study:
- To investigate the efficacy and safety of dalfampridine as a potential treatment for patients with hereditary spastic paraplegia (HSP).
Main Methods:
- A prospective, uncontrolled, open-label trial involving 12 HSP patients.
- Participants received dalfampridine 10 mg twice daily for two weeks.
- Assessments included the Timed-25-Foot Walk Test, Spastic Paraplegia Rating Scale (SPRS), and MSWS-12.
Main Results:
- Significant improvements were observed in SPRS scores (p = 0.0195) and MSWS-12 scores (p = 0.0429) post-treatment.
- No serious adverse events were reported during the study period.
- The treatment demonstrated a positive impact on walking ability and quality of life.
Conclusions:
- Dalfampridine treatment yielded encouraging results for improving walking ability in HSP patients.
- The findings support further investigation into dalfampridine for managing hereditary spastic paraplegia.
